SK285427B6 - Prostriedky na orálne podanie s riadeným uvoľňovaním levosimendanu - Google Patents

Prostriedky na orálne podanie s riadeným uvoľňovaním levosimendanu Download PDF

Info

Publication number
SK285427B6
SK285427B6 SK1554-2000A SK15542000A SK285427B6 SK 285427 B6 SK285427 B6 SK 285427B6 SK 15542000 A SK15542000 A SK 15542000A SK 285427 B6 SK285427 B6 SK 285427B6
Authority
SK
Slovakia
Prior art keywords
levosimendan
release
composition
composition according
active ingredient
Prior art date
Application number
SK1554-2000A
Other languages
English (en)
Slovak (sk)
Other versions
SK15542000A3 (sk
Inventor
Ilkka Larma
Maarit B�Ckman
Saila Antila
Lasse Lehtonen
Original Assignee
Orion Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8551575&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK285427(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corporation filed Critical Orion Corporation
Publication of SK15542000A3 publication Critical patent/SK15542000A3/sk
Publication of SK285427B6 publication Critical patent/SK285427B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Detergent Compositions (AREA)
SK1554-2000A 1998-04-23 1999-04-23 Prostriedky na orálne podanie s riadeným uvoľňovaním levosimendanu SK285427B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI980901A FI980901A7 (fi) 1998-04-23 1998-04-23 Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
PCT/FI1999/000329 WO1999055305A2 (en) 1998-04-23 1999-04-23 Controlled release peroral compositions of levosimendan

Publications (2)

Publication Number Publication Date
SK15542000A3 SK15542000A3 (sk) 2001-08-06
SK285427B6 true SK285427B6 (sk) 2007-01-04

Family

ID=8551575

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1554-2000A SK285427B6 (sk) 1998-04-23 1999-04-23 Prostriedky na orálne podanie s riadeným uvoľňovaním levosimendanu

Country Status (37)

Country Link
US (1) US7045147B1 (enExample)
EP (1) EP1071397B1 (enExample)
JP (2) JP4566402B2 (enExample)
KR (1) KR100960597B1 (enExample)
CN (1) CN1248691C (enExample)
AR (1) AR019096A1 (enExample)
AT (1) ATE258425T1 (enExample)
AU (1) AU756641B2 (enExample)
BG (1) BG64839B1 (enExample)
BR (1) BR9909869A (enExample)
CA (1) CA2329234C (enExample)
CO (1) CO5070607A1 (enExample)
CZ (1) CZ295194B6 (enExample)
DE (1) DE69914472T2 (enExample)
DK (1) DK1071397T3 (enExample)
EA (1) EA002829B1 (enExample)
EE (1) EE04220B1 (enExample)
ES (1) ES2215379T3 (enExample)
FI (1) FI980901A7 (enExample)
GE (1) GEP20032906B (enExample)
HR (1) HRP20000704B1 (enExample)
HU (1) HUP0101458A3 (enExample)
ID (1) ID27987A (enExample)
IL (2) IL138951A0 (enExample)
MX (1) MXPA00010367A (enExample)
NO (1) NO329809B1 (enExample)
NZ (1) NZ507453A (enExample)
PL (1) PL197447B1 (enExample)
PT (1) PT1071397E (enExample)
RS (1) RS49962B (enExample)
SI (1) SI1071397T1 (enExample)
SK (1) SK285427B6 (enExample)
TR (1) TR200003102T2 (enExample)
TW (1) TWI224507B (enExample)
UA (1) UA68376C2 (enExample)
WO (1) WO1999055305A2 (enExample)
ZA (1) ZA200005632B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI20011465A0 (fi) * 2001-07-04 2001-07-04 Orion Corp Pyridatsinonijohdannaisen uusi käyttö
WO2004082615A2 (en) * 2003-03-14 2004-09-30 Nirmal Mulye A process for preparing sustained release tablets
FI20070521A7 (fi) * 2006-11-10 2008-05-11 Atacama Labs Oy Rakeita, tabletteja ja rakeistusmenetelmä
EP2306823A4 (en) 2008-06-30 2012-09-26 Tocagen Inc 5-FLUOROCYTOSINE FORMULATIONS AND USES THEREOF
JP2014172850A (ja) * 2013-03-07 2014-09-22 Capsugel Belgium Nv ハードカプセル製剤
CN105784895B (zh) * 2015-10-30 2018-05-22 成都欣捷高新技术开发有限公司 一种用高效液相色谱仪检测左西孟旦中杂质的方法
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス，インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症（ＰＨ－ＨＦ－ｐＥＦ）を治療するためのレボシメンダン

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ203684A (en) 1982-04-05 1986-06-11 Merck Sharp & Dohme Granular formulation for the stabilization of unstable drugs or food supplements
US4716042A (en) 1986-06-16 1987-12-29 American Home Products Corporation Stabilized coated aspirin tablets
GB8903130D0 (en) * 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
US5213811A (en) * 1991-09-13 1993-05-25 Sterling Drug Inc. Oral sustained-release drug compositions
GB2266841A (en) * 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
US5795909A (en) * 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
GB9614098D0 (en) 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A7 (fi) 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia
FI974578L (fi) * 1997-12-19 1999-06-20 Orion Yhtymae Oyj Menetelmä levosimendaanin antamiseksi
FI980902A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaanin stabiileja koostumuksia

Also Published As

Publication number Publication date
EP1071397B1 (en) 2004-01-28
GEP20032906B (en) 2003-02-25
HK1034032A1 (en) 2001-10-12
CA2329234C (en) 2008-06-10
EE200000617A (et) 2002-06-17
UA68376C2 (en) 2004-08-16
HUP0101458A2 (hu) 2002-03-28
JP2002512946A (ja) 2002-05-08
CN1248691C (zh) 2006-04-05
DK1071397T3 (da) 2004-04-05
KR20010071172A (ko) 2001-07-28
US7045147B1 (en) 2006-05-16
IL138951A (en) 2006-10-31
DE69914472D1 (de) 2004-03-04
CN1301163A (zh) 2001-06-27
CA2329234A1 (en) 1999-11-04
BG104959A (en) 2001-07-31
HUP0101458A3 (en) 2002-05-28
HRP20000704B1 (hr) 2009-11-30
JP2010083900A (ja) 2010-04-15
ATE258425T1 (de) 2004-02-15
YU63900A (sh) 2003-07-07
AU756641B2 (en) 2003-01-16
RS49962B (sr) 2008-09-29
DE69914472T2 (de) 2004-11-11
PT1071397E (pt) 2004-06-30
NO329809B1 (no) 2010-12-20
AR019096A1 (es) 2001-12-26
SI1071397T1 (en) 2004-06-30
FI980901A7 (fi) 1999-10-24
IL138951A0 (en) 2001-11-25
TR200003102T2 (tr) 2001-02-21
PL197447B1 (pl) 2008-03-31
KR100960597B1 (ko) 2010-06-07
WO1999055305A3 (en) 1999-12-29
NZ507453A (en) 2003-02-28
ZA200005632B (en) 2002-01-14
EP1071397A2 (en) 2001-01-31
CO5070607A1 (es) 2001-08-28
PL344078A1 (en) 2001-09-24
EA002829B1 (ru) 2002-10-31
NO20005313D0 (no) 2000-10-20
BR9909869A (pt) 2000-12-19
MXPA00010367A (es) 2002-06-04
WO1999055305A2 (en) 1999-11-04
TWI224507B (en) 2004-12-01
AU3524699A (en) 1999-11-16
NO20005313L (no) 2000-11-21
SK15542000A3 (sk) 2001-08-06
ES2215379T3 (es) 2004-10-01
ID27987A (id) 2001-05-03
HRP20000704A2 (en) 2001-04-30
BG64839B1 (bg) 2006-06-30
CZ295194B6 (cs) 2005-06-15
EE04220B1 (et) 2004-02-16
CZ20003780A3 (en) 2001-05-16
JP4566402B2 (ja) 2010-10-20
FI980901A0 (fi) 1998-04-23
EA200001098A1 (ru) 2001-04-23

Similar Documents

Publication Publication Date Title
EP1443917B1 (en) Tamsulosin tablets
EP0722720B1 (en) Novel sugar coating composition for application to compressed medicinal tablets
JP2010083900A (ja) レボシメンダンの制御放出経口用組成物
AU2009273747A1 (en) Atovaquone with a particle size diameter range (D90) of greater than 3 um to about 10 um
WO1998005306A1 (en) Controlled release tablet formulation of isosorbide-5-mononitrate
HK1034032B (en) Controlled release peroral compositions of levosimendan
IE970563A1 (en) A composition
HK1009935B (en) Novel sugar coating composition for application to compressed medicinal tablets

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20110423